Business Description
Marinomed Biotech AG
ISIN : ATMARINOMED6
Total Employee Number:
33Compare
Compare
Traded in other countries / regions
MARI.Austria93Z.Germany IPO Date
2019-02-04Description
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | -1.18 | |||||
Debt-to-Equity | -1.62 | |||||
Debt-to-EBITDA | 0.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -1.02 | |||||
Beneish M-Score | 11.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.8 | |||||
3-Year EPS without NRI Growth Rate | 53.7 | |||||
3-Year FCF Growth Rate | 45.1 | |||||
3-Year Book Growth Rate | -11.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.38 | |||||
9-Day RSI | 37.41 | |||||
14-Day RSI | 39.62 | |||||
3-1 Month Momentum % | -28.57 | |||||
6-1 Month Momentum % | -50.27 | |||||
12-1 Month Momentum % | -48.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.21 | |||||
Quick Ratio | 0.21 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 172.1 | |||||
Days Sales Outstanding | 17.48 | |||||
Days Payable | 182.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.9 | |||||
Shareholder Yield % | 95.72 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.51 | |||||
Operating Margin % | -3.19 | |||||
Net Margin % | 234.27 | |||||
EBITDA Margin % | 246.78 | |||||
FCF Margin % | -14.3 | |||||
OCF Margin % | -14.3 | |||||
ROE % | Neg. Equity | |||||
ROA % | 248.23 | |||||
ROIC % | -1.26 | |||||
3-Year ROIIC % | -261.49 | |||||
ROC (Joel Greenblatt) % | 401.87 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.91 | |||||
Forward PE Ratio | 5.93 | |||||
PE Ratio without NRI | 4.63 | |||||
Price-to-Owner-Earnings | 0.95 | |||||
PS Ratio | 2.14 | |||||
EV-to-EBIT | 1.54 | |||||
EV-to-Forward-EBIT | 10.74 | |||||
EV-to-EBITDA | 1.52 | |||||
EV-to-Forward-EBITDA | 9.57 | |||||
EV-to-Revenue | 3.75 | |||||
EV-to-Forward-Revenue | 3.02 | |||||
EV-to-FCF | -26.22 | |||||
Price-to-GF-Value | 0.5 | |||||
Earnings Yield (Greenblatt) % | 64.94 | |||||
FCF Yield % | -5.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Marinomed Biotech AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.691 | ||
| EPS (TTM) (€) | 10.148 | ||
| Beta | 0.091 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.57 | ||
| Volatility % | 47.2 | ||
| 14-Day RSI | 39.62 | ||
| 14-Day ATR (€) | 0.279562 | ||
| 20-Day SMA (€) | 9.41 | ||
| 12-1 Month Momentum % | -48.18 | ||
| 52-Week Range (€) | 8.65 - 21.1 | ||
| Shares Outstanding (Mil) | 2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marinomed Biotech AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marinomed Biotech AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Marinomed Biotech AG Frequently Asked Questions
What is Marinomed Biotech AG(FRA:93Z)'s stock price today?
The current price of FRA:93Z is €8.80. The 52 week high of FRA:93Z is €21.10 and 52 week low is €8.65.
When is next earnings date of Marinomed Biotech AG(FRA:93Z)?
The next earnings date of Marinomed Biotech AG(FRA:93Z) is .
Does Marinomed Biotech AG(FRA:93Z) pay dividends? If so, how much?
Marinomed Biotech AG(FRA:93Z) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico | 2023-08-01 |
Articles on Marinomed Biotech AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers